THE FUTURE OF INJECTION-LIPOLYSIS / LIPODISSOLVE
10 years NETWORK-Lipolysis - commentary of NETWORK speaker Dirk Brandl...
During the last decade the NETWORK has grown up. 10 years ago we started in a small group and had to prove the efficacy of our fat reducing injectable. The NETWORK members developed a standard protocol to offer a safe therapy to their patients. Cooperating universities like the Regensburg University and the Ruhruniversity Bochum contributed in cooperation with their studies to decode the mechanism of action.
When we look back we can see more than 180 trainings with 3.000 physicians from 64 countries, more than 300.000 treatments, and more than 50 publications by NETWORK members. Nowadays injection-lipolysis has become a well accepted therapy in the treatment regime of many aestheticians.
During the last decade the members have developed new and better options for the treatment, and still they do. The last step was the invention of the PSM - the Pain and Side Effect Management, which has reduced the side effects and increased the patient acceptance.
What will be the future of injection-lipolysis (lipodissolve)?
1 - the active agents
Until now the active agents are PPC-DOC. Polyenylphosphatidylcholine is a lecithin with high unsaturated fatty acids. Deoxycholic acid is a bile acid. Up to now we can say that DOC is responsible for the destruction of the cell membrane. This is the reason why Kythera (and earlier Bayer in cooperation with Kythera) tried to approve single DOC for the fat reduction of the double chin. Since we have started with injection-lipolysis we discuss the issue, if PPC is necessary or not for the treatment. Our members are convinced that a mix with PPC-DOC is the best. If Kythera is successful with the approval we would welcome an approved drug, but we also would discuss further on the effects of PPC on the therapy. The Network itself has developed in cooperation with a Russian institute a new patented solution without DOC, and we are sure that this will be the future in IL treatment.
2 - combination therapies
We always look at other tools with a fat reducing effect and if we are able to reduce the side effects of IL like pain, swellings, reddening, haematomas etc. and if we can raise the effects. Last year NETWORK member Prof. Irene Tausch has done a half side comparison study with the LDM ultrasound device, a special device that is able to change the frequencies within one application (dual frequency ultrasound). The publication about the study is on the way. The results: Pain reduction and a 65% better effect. Another half side comparison study is at the moment ongoing with a shock wave device from Zimmer.
3 - better patient selection by differential diagnosis
During the Aesthetic Holidays 2014 which took place in Mallorca, Spain, we tested a new ultrasound device for skin analysis. What we have seen with this device enables us to have a better rating about the result in every patient. A study about this tool will be made by Dr. Steinert, vice director of the NETWORK-Lipolysis.